anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Acute pancreatitis (AP) is a common inflammatory response that occurs in the pancreas with mortality rates as high as 30 %. However, there is still no consistent and effective treatment for AP now. MicroRNA-148 was reported to be involved in AP through IL-6 signaling pathway. Therefore, we aimed to further explore the detailed mechanisms of AP, to develop more therapeutic approach for AP. Exosomes were isolated from peripheral blood mononuclear cells of 20 AP patients and 20 healthy volunteers to evaluate the abnormally expressed miRNA. Then pancreatic acinar cells (PACs) were transfected with retrovirus to overexpress miR-148a/miR-551b-5p to evaluate their function. Both miR-148a and miR-551b-5p were highly expressed in AP patients than these in healthy cases. Then overexpressing miR-551b-5p in PACs could regulate autophagy through directly binding to Baculoviral IAP Repeat Containing 6, leading to the increased secretions of interleukin-1β (IL-1β) and interleukin-18 (IL-18) through interleukin-1 (IL-1) signaling pathway. Moreover, overexpressing miR-148a in PACs could decrease the secretions of IL-1β and IL-18 to modulate autophagy. The exosomal miRNA-148a and miRNA-551b-5p derived from peripheral blood mononuclear cells of AP patients may two-way mediate autophagy damage through IL-6/STAT3 signaling pathway, which participated in the AP pathogenesis. Our findings may provide new targets for the diagnosis and treatment of AP.
PURPOSE:A cosmetic, obtained by incorporating soluble collagen and a derivative thereof with allantoin and a derivative thereof, and having improved effect on improvment in skin roughening and more synergistically enhanced effect thereof than in individual use thereof. CONSTITUTION:A cosmetic, containing one or two or more selected from the group consisting of soluble collagen and derivatives thereof, e.g. soluble succinylated collagen, in an amount of 0.001-1.5wt% based on the total weight of the cosmetic and one or two or more selected from the group consisting of allantoin of the formula and derivatives thereof, e.g. hydroxyaluminum allantoate, in an amount of 0.01-5.0wt%, preferably 0.05-3.0wt%, and having improved effect on improvement in skin roughening. The form of the cosmetic may be a nutrient cream, hand cream, body cream, milky lotion, lotion and pack, etc. A surfactant, oil, humectant, etc. may be suitably incorporated with the cosmetic in addition to the essential components.
The article "BNIP1 inhibits cell proliferation, migration and invasion, and promotes apoptosis by mTOR in cervical cancer cells", by F.-H. Li, L. Xiang, L. Ran, S. Zhou, Z. Huang, M. Chen, W.-F. Yu, published in Eur Rev Med Pharmacol Sci 2019; 23 (4): 1397-1407-DOI: 10.26355/eurrev_201902_17096-PMID: 30840260 has been retracted by the Editor in Chief for the following reasons. Following some concerns raised on PubPeer regarding a possible overlap in Figure 2A, the Editor in Chief has started an investigation to assess the validity of the results as well as possible figure manipulation. The journal investigation revealed a duplication in Figure 2A between BNIP1 panels, migration and invasion, respectively and in Control and invasion panels. Consequently, the Editor in Chief mistrusts the results presented and has decided to withdraw the article. The authors have been informed about the journal's investigation but remained unresponsive. https://www.europeanreview.org/article/17096 This article has been retracted. The Publisher apologizes for any inconvenience this may cause.
A system is provided to monitor, over time, one or more physical variables related to a severity or progression of a movement disorder and/or of symptoms thereof. The monitored physical variables can include speech sounds; keyboard outputs; or accelerations, rotations, or other properties of the motion of one or more body parts. The system operates to detect, based on the monitored one or more physical variables, potential changes in the degree and/or character of the movement disorder symptoms. In response to detecting such a potential change, the system provides the user with one or more tasks that the user can perform. The system detects one or more properties of the user's performance and, based on that detection, determines the severity or progression of the movement disorder. The tasks can include stepping, turning, standing, sitting, reaching, typing, pointing, manipulating an object, speaking into a microphone, or other tasks.
PURPOSE:To obtain a novel compound having antagonism against GPIIbIIIa receptor on the surface of platelet and high safety and useful as an antithrombotic agent and a platelet aggregation inhibitor. CONSTITUTION:A compound of the formula (R1 is amidino substituted at O-, m- or p-position or protected amidino; A is lower alkylene which have a substituent group or alkylene which may have phenylene; B is CONH or CH2; R2 is ester, amide, etc.; R3 is H, alkyl, etc.) and its salt, e.g. 3-[4-(4-aminodiphenoxy) butanoylamino]propionic acid sodium salt. This compound is obtained by reacting a corresponding cyanophenyl ether derivative such as ethyl 3-[4-(4- cyanophenoxy)butanoylamino]propionate with hydrogen chloride in an alcohol solvent and then reacting the product with ammonium chloride or ammonia.
Provided are mechanisms and processes for an infant data aggregation system. The system includes a platform interface and a platform processor. A platform interface is configured to receive measurement data from multiple infant monitoring systems, each of the multiple infant monitoring systems including an infant monitoring device and an infant monitoring hub. Each of the plurality of infant monitoring systems is associated with a corresponding infant. A platform processor is configured to remove personally identifiable information associated with the measurement data to generate infant de-identified data and analyze the measurement data from the plurality of infant monitoring systems to generate a dynamic model reflecting infant trends associated with infants of different ages. The dynamic model is viewable by users associated with infant monitoring systems. The platform interface may be further configured to send the dynamic model to a first infant monitoring system.
1,210,508. Tin (II) chelates. DOW CHEMICAL CORP. 27 Nov., 1967, No. 83891/67. Heading C2C. Novel water-soluble fluorostannous chelates of N-containing chelating agents having as chelating groups (1) a hydroxyalkyl group and (2) a carboxyalkyl group, the N-atom and the two chelating groups being so positioned in the structure that they form with the fluorostannous component of the chelate a 6 to 10 membered ring, are prepared by mixing in aqueous solution, under an inert atmosphere, stannous fluoride and the requisite chelating agent. The free carboxylic acid groups may be at least partially neutralized e.g. a Ca salt of pH 5 to 8. The following chelates are exemplifled.
The invention discloses Lactobacillus paracasei JN-1 and application thereof, wherein the Lactobacillus paracasei JN-1 is preserved in the common microorganism center of China microorganism culture preservation management committee in 2021 for 21 months in 6 months, the preservation address is No. 3 of Xilu No. 1 of Beijing market on the sunward district, and the preservation number is CGMCC No. 22745. The Lactobacillus paracasei JN-1 has the advantages that the simulated digestion survival rate in gastrointestinal fluids reaches 82%, the cholate resistance is strong, and when the cholate concentration reaches 0.6%, A is BS The lactobacillus paracasei JN-1 has strong bacteriostatic activity in vitro, shows obvious bacteriostatic effect on staphylococcus aureus and shows good inhibitory action. The Lactobacillus paracasei JN-1 of the invention hasHas strong resistance of gastrointestinal digestive system and bile salt tolerance, can be used for preventing and treating spontaneous enteritis, and has good function and flavor.
Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
Detailed Description: In this single-blind randomized clinical trial, 60 women aged 25-65 yrs with stress urinary incontinence were randomly divided in two groups by blocked randomization method; behavioral intervention program (n=30) and insertion vaginal device,vaginal cones (n=30). Women in behavioral intervention group were instructed for pelvic floor exercise and bladder control strategies. Other group was allocated to use vaginal cones. They were treated for 12 weeks and followed up every 2 weeks. The subjective changes in severity of SUI were measured using a Detection SUI Severity Questionnaire and leakage index and 3-day urinary dairy. The objective changes were measured by pad test. These two groups were then compared according to the scores of special questionnaires for quality of life, strength of pelvic floor muscles, capability to participate in social activities, severity of urinary incontinence, and the number of involuntary urine passage, taken before, and after 1 and 3 months after finishing interventions. Data analysis will be done through descriptive and perceptive statistical methods by using SPSS.
The present invention provides a traditional Chinese medicine composition for curing osteoporosis, which is prepared from effective components and pharmaceutically acceptable adjuvant materials, wherein the effective components are mainly prepared from hairy deerhorn, epimedium herb, psoralea fruit, herba cistanchis, common cnidium fruit and fructus. The effective components of the present invention have the effects of kidney replenishment, yang warming, essence replenishment and bone strengthening, and are mainly suitable for primary osteoporosis which belongs to a kidney yang vacuity type through the syndrome differentiation of traditional Chinese medicine. The traditional Chinese medicine composition of the present invention can remarkably increase animal blood calcium content, raise estrogen levels, inhibit bone resorption, and promote bone formation. Bone metabolism is in a positive balance state that the bone formation is larther than the bone resorption, and finally, bone mass is increased. Therefore, the purposes of the prevention and the cure of osteoporosis are realized. The prevention effect and the cure effect of the traditional Chinese medicine composition of the present invention on osteoporosis is obviously better than estradiol as positive control medicine and a dragon bone oyster shell bone strengthening powder preparation. In addition, the present invention also provides a preparation method for the traditional Chinese medicine composition.
Tooth scheduled for extraction will be removed in the least traumatic way. The socket will be filled with the investigational device (WHA, granules 0.25- 1.0mm). Two follow up visits to monitor the healing process will take place at 2 and 6 weeks after surgery. Implant placement will be performed 4 months after the regenerative procedure. Implant loading will be allowed after having waited a minimum of 3 months after the implant placement and after a control visit. The implant survival and success will be assessed at 3, 6 and 12 months after implant placement. A long-term follow-up will evaluate the implant survival and success at 3 and 5 years post implant placement.
Q is -N= or CR2; X is S, O or NOR3, Y is -O-, -S-, -SO-, -SO2-, R and R1 are each, independently, H, a substituent or unsubstituted aliphatic, aromatic, heteroaromatic or aralkyl group, R2 is H or a substituent, R3 is H, or -C(O)R4, R4 is a substituted or unsubstituted aliphatic or aromatic group, n is an integer from 0 to 1. Chemical compounds having structural formula and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the tyrosine kinases, whose activity is inhibited by these chemical compounds, are involved in angiogenic processes. Thus, these chemical compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compounds can be used to treat cancer and hyperproliferative disorders. 36 claims
In addition to the exercises applied to the participants in the control group, the participants in this group used Mobilization with movement, which was performed with the principle of painless movement 3 times a week for a total of 12 times a week for 4 weeks. Mobilization with movement has been performed by a certified physiotherapist who has been practicing this technique for 10 years.
Individuals interested in participating in the study will be randomized to receive access to a 12-week internet-based treatment group. Subjects assigned to the treatment group will have access to a group discussion board, a structured 12-week coping-skills training course, professional facilitation of the group, a real-time chat board, and personal profiles established by other group members. Subjects will be asked to complete online self-report measures of distress, mood disturbance, and quality of life at baseline and again after participation in the 12-week group.
We recently reported in a rat model of kidney transplantation that the addition of sodium thiosulfate (STS) to organ preservation solution improved renal graft quality and prolonged recipient survival. The present study investigates whether STS pre-treatment would produce a similar effect. In vitro, rat kidney epithelial cells were treated with 150 μM STS before and/or during exposure to hypoxia followed by reoxygenation. In vivo, donor rats were treated with PBS or 2.4 mg/kg STS 30 min before donor kidneys were procured and stored in UW or UW+150 μM STS solution at 4 °C for 24 h. Renal grafts were then transplanted into bilaterally nephrectomised recipient rats which were then sacrificed on post-operative day 3. STS pre-treatment significantly reduced cell death compared to untreated and other treated cells in vitro (p < 0.05), which corresponded with our in vivo result (p < 0.05). However, no significant differences were observed in other parameters of tissue injury. Our results suggest that STS pre-treatment may improve renal graft function after transplantation.
BACKGROUND: Ironman-distance events are ultra-endurance competitions involving three sports, leading to various adverse medical incidents. While some athletes compete in the same event over multiple years, medical trends among repeat competitors have not been studied. This study aimed to determine the recurrence of common medical incidents in repeat competitors over time in a longstanding Ironman-distance championship event.
METHODS: Data were collected using standardized sheets completed by nurses and physicians during athlete medical evaluations from 1989-2019. Competitors (N.=427) were included in the analysis if they received medical evaluation in at least three competitions within a fifteen-year period. Bivariate correlations were calculated to determine associations among medical incidents during competitors' first year of medical evaluation. Logistic regression analyses were performed to investigate the likelihood of medical incidents reoccurring in subsequent years following the initial occurrence.
RESULTS: Significant associations were found between several adverse medical incidents during competitors' first medical evaluations and for those evaluated in 3+ years. Competitors diagnosed with hyponatremia (aOR=2.42, 95% CI: 1.07-5.46), nausea (aOR=1.83, 95% CI: 1.14-2.94), dizziness (aOR=1.71, 95% CI: 1.09-2.68), and muscle cramps (aOR=1.62, 95% CI: 1.05-2.50) during their first year were significantly more likely to return with the same issue in subsequent years. In contrast, those who experienced vomiting during their first year were less likely to return for the same problem (aOR=0.45, 95% CI: 0.27-0.77).
CONCLUSIONS: There are significant correlations and clear patterns of recurrence for specific medical incidents among elite ultra-endurance triathletes. Further analyses of other triathlon repeat populations and more specific examinations by age and sex are needed.
Participants allocated to the waitlist-control condition will be given minimal intervention in standard practices at baseline and 3-month. It consist of general health education and advice, where the health information is open resources available for the public. No risk-stratified services nor active referral will be conducted by nurse until 6-month assessment is completed. After that, they will immediately receive intervention based on their 6-month assessment, and booster interventions at 7-month contact and 12-month follow-up.
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs, yet its underlying mechanisms remain unclear, and precise biomarkers are lacking. In this study, we employed Mendelian randomization and HEIDI tools to comprehensively analyze large-scale Genome-Wide Association Study (GWAS) and expression Quantitative Trait Loci (eQTL) data, leading to the identification of seven novel potential functional genes associated with SLE, including BLK, ELF1, STIM1, B3GALT6, APOLD1, INPP5B, and FHL3. Subsequent investigations revealed a significant downregulation of ELF1 gene expression in CD4+ T cells of SLE patients compared to healthy controls. Moreover, within various SLE subgroups, such as those with decreased serum complement C3 levels, positive urinary protein, new-onset skin rashes, and SLE Disease Activity Index (SLEDAI) scores ≥ 5, ELF1 expression displayed a consistent decreasing trend. Notably, ROC curve analysis highlighted the diagnostic potential of ELF1 expression in SLE (AUC = 0.9493), as well as its value in assessing disease activity (AUC = 0.6852) and renal involvement (AUC = 0.7363). In conclusion, this study underscores the potential of ELF1 as a SLE biomarker for diagnosis and evaluation, offering insights into the underlying mechanisms of SLE and paving the way for future therapeutic research.
The invention discloses an optical-activity 2-hydroxytetrahydrothienopyridine derivative, a preparation method and application thereof in pharmacy. The derivative is a compound shown in a formula I in the specification and comprises a salt of the compound shown in the formula I and an enantiomer and a raceme of the compound shown in the formula I. According to results form pharmacodynamics experiments, the compound shown in the formula I has an obvious effect on inhibiting platelet aggregation, and the effect on resisting the platelet aggregation, of partial compounds, is obviously better than that of clopidogrel. According to results from pharmacokinetics experiments, the compound shown in the formula I can be effectively converted into a pharmacological active metabolin to exert the effect on inhibiting the platelet aggregation and has the bioavailability obviously higher than that of the clopidogrel. Therefore, the compound shown in the formula I can be used for preparing medicines for preventing or treating diseases related to thrombus and embolism. The invention further provides a preparation method of the compound shown in the formula I.
The oral LD50 of spironolactone is greater than 1000 mg/kg in mice, rats, and rabbits. The oral LD50 of hydrochlorothiazide is greater than 10 g/kg in both mice and rats.

Acute overdosage of spironolactone may be manifested by drowsiness, mental confusion, maculopapular or erythematous rash, nausea, vomiting, dizziness, or diarrhea. Rarely, instances of hyponatremia, hyperkalemia (less commonly seen with spironolactone and hydrochlorothiazide because the hydrochlorothiazide component tends to produce hypokalemia), or hepatic coma may occur in patients with severe liver disease, but these are unlikely due to acute overdosage.

However, because spironolactone and hydrochlorothiazide tablets contain both spironolactone and hydrochlorothiazide, the toxic effects may be intensified, and signs of thiazide overdosage may be present. These include electrolyte imbalance such as hypokalemia and/or hyponatremia. The potassium-sparing action of spironolactone may predominate and hyperkalemia may occur, especially in patients with impaired renal function. BUN determinations have been reported to rise transiently with hydrochlorothiazide. There may be CNS depression with lethargy or even coma.
FIELD: medicine. SUBSTANCE: the innovation refers to new chemical substances of general formula:   where M'-cation of alkaline metal, M - cation of d- metal or alkaline-earth metal, GluTrp - anion of glutamyltryptophan, n - amount of alkaline metal atoms, m - amount of water molecules. Declared compounds reveal immunostimulating action upon an alive organism. In declared solution the method is suggested to obtain glutamyltryptophan metalocomplexes and implies that glutamyltryptophan or its salt interact in aqueous medium at 0-100 C at equivalent amount of water-soluble d-metal salt or alkaline-earth metal or their hydroxides, or oxides, or carbonates, or main carbonates with subsequent precipitation of a target product by using an organic solvent. Moreover, interaction of reacting components and precipitation of a target product take place at the atmosphere corresponding to redox-properties of metal. EFFECT: enhanced assortment of immunostimulating preparations. 3 cl, 7 ex, 5 tbl
Ten patients in the treatment group and 10 patients in the control group were enrolled in this prospective, randomized, double blinded study. Two weeks after myocardial infarction that was accompanied by successful recanalization and stent implantation, the patients of the treatment group received 10 μg/kg body weight per day (divided BID) G-CSF subcutaneously for treatment duration of maximum 5.0 days. In both groups, ejection fraction was evaluated with echocardiography and cardiac scan (Gated SPECT method) 10 days after myocardial infarction and after 6 months. Tei index was measured by echocardiography.

Results: No severe side effects of G-CSF treatment were observed. Ejection fraction determined by cardiac scan increased in the treatment group from 0.428 to 0.462 and from 0.470 to 0.496 in the control group but there was no significant improvement of left ventricular ejection fraction when the G-CSF treated group was compared to the controls (p=0.821 for cardiac scan and p=0.705 for echocardiography). Changes in Tei index was not significant in the treatment group (p=0.815) however it reached significant level in the control group (p=0.005), respectively.